CTOR Stock Summary and Trading Ideas (Citius Oncology | NASDAQ:CTOR)

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Citius Oncology trades on the NASDAQ stock market under the symbol CTOR.

As of December 23, 2025, CTOR stock price declined to $1.21 with 210,026 million shares trading.

CTOR has a beta of 1.93, meaning it tends to be more sensitive to market movements. CTOR has a correlation of 0.05 to the broad based SPY ETF.

CTOR has a market cap of $102.61 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that CTOR belongs to (by Net Assets): VTI, VXF, IWC.

CTOR has outperformed the market in the last year with a price return of +23.7% while the SPY ETF gained +17.4%. However, in the short term, CTOR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -32.0% vs +3.3% return in SPY. But in the last 2 weeks, CTOR shares have fared better than the market returning +11.0% compared to SPY +0.8%.

CTOR support price is $1.12 and resistance is $1.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTOR shares will trade within this expected range on the day.